News | Heart Failure | August 18, 2015

Sunshine Heart Resumes Enrollment in COUNTER HF Study

Trial investigators perform first implant of C-Pulse System after pause generated by series of deaths during early enrollment

Sunshine Heart, COUNTER HF pivotal study, resumes enrollment, C-Pulse, FDA

August 18, 2015 — Sunshine Heart Inc. announced an update in late July on its COUNTER HF U.S. pivotal study for the C-Pulse Heart Assist System. COUNTER HF is a prospective, randomized, multi-center, controlled study evaluating the safety and efficacy of the C-Pulse system for the treatment of New York Heart Association (NYHA) Class III and ambulatory Class IV heart failure. The study was temporarily paused this past March after the company notified the U.S. Food and Drug Administration (FDA) of four deaths in the treatment arm of the study. The deaths were adjudicated as not device- or therapy-related, and as previously announced on May 26th, the FDA approved resumption of patient enrollment in the study.

Immediately following the FDA's decision to approve enrollment to continue the COUNTER HF's study, Sunshine Heart distributed material to all sites with the necessary documentation in order to achieve site Investigational Review Board (IRB) approvals. Currently, 12 sites have been reactivated, which is approximately half of all previously activated sites. Sunshine Heart expects the majority of sites to be reactivated by the end of August.

In addition, the company announced the enrollment of its first two patients since the resumption of the COUNTER HF study. One of these patients was already reviewed by Sunshine Heart's newly formed Physician Subject Selection Committee. This led to the first implant being scheduled for the morning of July 23.

The C-Pulse System is an investigational device in the United States and Canada that utilizes the scientific principles of intra-aortic balloon counter-pulsation applied in an extra-aortic approach to assist the left ventricle by reducing the workload required to pump blood throughout the body, while increasing blood flow to the coronary arteries. Combined, these potential benefits may help sustain the patient's current condition or, in some cases, reverse the heart failure process, thereby potentially preventing the need for later-stage heart failure devices, such as left ventricular assist devices (LVADs), artificial hearts or transplants.

For more information: www.sunshineheart.com

Related Content

Guideline Adherence, Not Patient Volume, May Be Better Hospital Heart Failure Metric
News | Heart Failure | February 01, 2018
February 1, 2018 –  In evaluating the quality of care given to those hospitalized with...
First-in-Man RenalGuard Studies Show Promise for Heart Failure Patients
News | Heart Failure | January 02, 2018
RenalGuard Solutions Inc. reported positive results from a first-in-man feasibility study focusing on a novel use of...
ACC Issues New Guidance to Optimize Heart Failure Treatment
News | Heart Failure | December 22, 2017
December 22, 2017 — To help streamline treatment of patients with...
Coffee Associated With Reduced Risk of Heart Failure, Stroke. AHA 2017. #AHA2017
News | Heart Failure | November 25, 2017
November 25, 2017 — Drinking coffee may be associated with a decreased risk of developing heart failure or having str
Heart failure associated with methamphetamine (meth) use has risen dramatically in recent years among U.S. veterans, according to preliminary research presented at the 2017 American Heart Association (AHA) Scientific Sessions.
News | Heart Failure | November 25, 2017
November 25, 2017 — Heart failure associated with methamphetamine (meth) use has risen dramatically in recent years a
The Corvia intra-atrial shunt to treat diastolic heart failure.

The Corvia intra-atrial shunt to treat diastolic heart failure.

Feature | Heart Failure | November 25, 2017
November 25, 2017 – Results presented at the 2017 American Heart Association (AHA) Scientific Sessions and published
Surgery Could Reduce Frailty in Adults With Heart Failure
News | Heart Failure | November 17, 2017
November 17, 2017 — Common practice, and recently published research, shows that the risk of complications with surge
News | Heart Failure | November 13, 2017
November 10, 2017 — Moderna Therapeutics announced a new license and collaboration with AstraZeneca to co-develop and
Scientists Reverse Advanced Heart Failure in Mouse Model
News | Heart Failure | October 30, 2017
October 30, 2017 — Researchers have discovered a previously unrecognized healing capacity of the heart.
Trial Data Shows Positive Predictive Results for Boston Scientific HeartLogic Heart Failure Diagnostic
News | Heart Failure | October 20, 2017
October 20, 2017 — Boston Scientific announced new data from the Multisensor Chronic Evaluation in Ambulatory Heart F
Overlay Init